Dow Up2.00% Nasdaq Up1.66%

aTyr Pharma Inc. (LIFE)

4.11 Up 0.31(8.16%) Feb 12, 4:00PM EST
ProfileGet Profile for:
aTyr Pharma Inc.
3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States - Map
Phone: 858-731-8389
Fax: 858-731-8394

Index Membership:N/A
Full Time Employees:49

Business Summary 

aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on aTyr Pharma Inc.

Corporate Governance 
aTyr Pharma Inc.’s ISS Governance QuickScore as of Feb 1, 2014 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. John D. Mendlein Ph.D., J.D., 56
Chief Exec. Officer and Director
Dr. Paul R. Schimmel Ph.D., 75
Founder, Director and Member of Compensation Committee
Xiang-Lei Yang Ph.D.,
Mr. Stan Blackburn ,
Acting Chief Financial Officer and Financial Consultant
Mr. John T. Blake CPA, 40
Principal Accounting Officer and VP of Fin.
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders